WO2001079196A2 - 1-(h-1,2,4-triazol-1-yl)butan-2-ol derivatives - Google Patents
1-(h-1,2,4-triazol-1-yl)butan-2-ol derivatives Download PDFInfo
- Publication number
- WO2001079196A2 WO2001079196A2 PCT/EP2001/003956 EP0103956W WO0179196A2 WO 2001079196 A2 WO2001079196 A2 WO 2001079196A2 EP 0103956 W EP0103956 W EP 0103956W WO 0179196 A2 WO0179196 A2 WO 0179196A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- thiadiazol
- triazol
- butan
- formula
- thiazol
- Prior art date
Links
- 0 C[C@@](**CSCN)[C@@](*)(C[n]1ncnc1)O Chemical compound C[C@@](**CSCN)[C@@](*)(C[n]1ncnc1)O 0.000 description 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Definitions
- Azole antifungal agents are currently most frequently used for systemic mycosis, but none of them fully fulfil the necessary clinical requirement; such as efficacy against major systemic mycoses including disseminated aspergillosis, safety, and water solubility for parenteral formulation.
- major systemic mycoses including disseminated aspergillosis, safety, and water solubility for parenteral formulation.
- the systematic mycoses caused by Candida, Cryptococcus and Aspergillus spp. are still major infections, there is an increasing medical need for new antifungal agents with broader spectrum that cover not only the above mentioned major pathogens but also emerging pathogens such as mucor spp.
- Several new azole type agents have been developed to fulfil these unmet medical needs, such as the compounds disclosed in EP 0 667 346 and EP 0 440 372.
- the present invention intends to provide antifungal agents having broad antifungal spectrum covering Aspergillus as well as mucor spp., their intermediates
- the present invention provides compounds with a much broader antifungal spectrum compared to existing azoles. Namely, the compounds of the present invention have a surprisingly high level of antifungal activity, in particular against Aspergillus spp., and mucor spp. such as Rhizopus spp., and Absidia spp.
- the present invention relates to novel l-(lH-l,2,4-triazol-l-y ⁇ )butan-2-ol derivatives of the formula (I),
- Q is a phenyl ring, optionally substituted by 1 to 3 halogen atom(s);
- R is hydrogen, hydroxy, carboxy, carbamoyl, cyano, lower-alkyl, lower - alkoxycarbonyl or lower-alkoxy, whereas lower-alkyl, lower- alkoxycarbonyl and lower-alkoxy may be substituted by one or more halogen, lower-alkyl, di-lower-alkylamino or lower-alkoxy;
- X is a 5 or 6 membered hetero-aromatic ring
- Y is phenyl or pyridyl, each of which may be substituted by one or more halogen, cyano, lower-alkyl, di-lower-alkylamino, lower-alkyloxy, acyl, lower-alkoxycarbonyl;
- Z is a sulfur and nitrogen containing 5 membered hetero-aromatic ring
- the present invention also relates to pharmaceutical compositions containing above l-(lH-l,2,4-triazol-l-yl)butan-2-ol derivatives, the use of such derivatives for the prophylaxis or treatment of mycoses as well as to processes for production of such l-(lH-l,2,4-triazol-l-yl)butan-2-ol derivatives.
- lower is used to mean a radical consisting of 1 to 5, preferably 1 to 4 carbon atom(s), unless otherwise indicated.
- alkyl refers to a branched or straight chain monovalent saturated aliphatic hydrocarbon radical of one to twenty carbon atoms, preferably of one to sixteen carbon atom(s).
- lower alkyl refers to a branched or straight chain monovalent alkyl radical of one to six carbon atom(s), preferably one to four carbon atom(s). This term is further exemplified by such radicals as methyl, ethyl, n-propyl, isopropyl, n-butyl, i-butyl, tert-butyl and the like.
- halogen atom refers to fluorine, chlorine, bromine and iodine.
- heteroatom refers to N, O and S.
- acyl refers to the group -C(O)-R', where R' is a lower alkyl.
- lower alkoxycarbonyl refers to the group -C(O)OR', where R 1 is a lower alkyl.
- lower alkoxy refers to the group -O-R', where R 1 is a lower alkyl.
- di-lower alkylamino refers to two independently selected lower alkyl groups attached to a nitrogen atom, i.e., -N(-lower alkyl)-lower alkyl.
- sulfur and nitrogen containing 5 membered hetero-aromatic ring preferably means a group selected from the group consisting of the groups represented by the formula
- hetero-aromatic ring means a group selected from the group consisting of the groups represented by the formula:
- N N viz. thiazol-2,4-diyl and l,2,4-thiadiazol-3,5-diyl.
- phenyl or pyridyl which may be substituted by one or more halogen, cyano, lower-alkyl, di-lower-alkylamino, lower-alkyloxy, acyl, lower-alkoxycarbonyl
- Y preferably means o-phenylene, m-phenylene, p- phenylene, pyridin-2,4-diyl, pyridin-2,5-diyl, pyridin-2,6-diyl and the like. More preferably, Y is m-phenylene, p-phenylene or pyridin-2,5-diyl. The most preferable Y is p-phenylene.
- Preferable residues R in accordance with the present invention are hydrogen, hydroxy, lower-alkyl, e.g. methyl or ethyl, lower-alkoxycarbonyl, e.g. ethoxy- carbonyl, and lower-alkyl substituted by one or more halogen, preferably fluoro, e.g. trifluoromethyl or pentafluoroethyl.
- -Z-R in the formula (I) are thiazole-2-yl, 4- methyl-thiazol-2-yl, 4-isopropyl-thiazol-2-yl, 4-ethyl-thiazol-2-yl, 4- trifluoromethyl-thiazol-2-yl, 4-pentafluoroethyl-thiazol-2-yl, 4-acetyl-thiazol-2-yl, 4-carboxy-thiazol-2-yl, 4-cyano-thiazol-2-yl, 4-methoxy-thiazol-2-yl, 4- etnoxycarbonyl-fhiazol-2-yl, 4-chloro-thiazol-2-yl, 4-hydroxy-thiazol-2-yl, 1,2,4- thiadiazol-3-yl, 5-methyl-l,2,4-fhiadiazol-3-yl, 5-ethyl-l,2,4-thiadiazol-3-yl, 5- isopropyl
- phenyl ring optionally substituted by 1 to 3 halogen atom(s) preferably means 2-fluorophenyl, 4-fluorophenyl, 2- chlorophenyl, 4-chlorophenyl, 2-bromophenyl, 2,4-dichlorophenyl, 2,4- difluorophenyl, 2-chloro-4-fluorophenyl, 2-fluoro-4-chlorophenyl, 2,5- difluorophenyl, 2,4,6-trifluorophenyl, 4-bromo-2,5-difluorophenyl and the like; more preferably 2-fluorophenyl, 4-fluorophenyl, 2,4-difluorophenyl, 2,5- difluorophenyl, 2,4,6-trifluorophenyl, 4-bromo-2,5-difluorophenyl.
- the most preferable residues Q are 2,4-difluorophenyl and
- the present invention relates to 1-(1H-1,2,4- triazol-l-yl)butan-2-ol derivatives of the above formula (I) wherein Q is a radical selected from the group consisting of 2,4-difluorophenyl and 2,5-difluorophenyl; X is a radical selected from the group consisting of l,2.4-thiadiazol-3,5-diyl and thiazol-2,4-diyl; Y is p-phenylene; Q is 2,4-difluorophenyl or 2,5-difluorophenyl; and -Z-R is a radical selected from the group consisting of l,2,3-thiadiazol-4-yl and thiazole-2-yl.
- Q is a radical selected from the group consisting of 2,4-difluorophenyl and 2,5-difluorophenyl
- X is a radical selected from the group consisting of l,2.4-thi
- Preferred l-(lH-l,2,4-triazol-l-y ⁇ )butan-2-ol derivatives in accordance with the present invention are as follows:
- novel l-(l ⁇ -l,2,4-triazol-l-yl)butan-2-ol derivatives of the formula (I) can be produced by one or more of the following methods:
- compound of the formula (IN) may include, for example, the following compounds: (2R,3R)-2-(2,4-difluorophenyl)-3- ⁇ 4-[4- (l,2,3-thiadiazol-4-yl)phenyl]thiazol-2-yl ⁇ -l-(lH-l,2,4-triazol-l-yl)butan-2-ol,
- This reaction proceeds in a solvent such as chloroform, dichloromethan, acetonitrile, dimethylformamide, methanol, ethanol, and the like, and at temperature between 0°C and 100°C for between 1 to 12 hours, preferably at 20°C to 60°C.
- a solvent such as chloroform, dichloromethan, acetonitrile, dimethylformamide, methanol, ethanol, and the like.
- the desired l-(lH-l,2,4-triazol-l-yl)butan-2-ol derivatives of the formula (I) in which X ,Y and Q are the same as defined above and -Z-R is fhiazol-2-yl can be produced by condensation of a compound represented by the formula (N) wherein Q is the same as defined above with an ⁇ -bromoketone represented by the formula (VI):
- Specific examples of the compound represented by the formula (Nil) may include, for example, the following compounds: (2R,3R)-2-(2,4-difluorophenyl)-3- ⁇ 4- [4-(thiazol-2-yl)phenyl]thiazol-2-yl ⁇ -l-(lH-l,2,4-triazol-l-yl)butan-2-ol, (2R,3R)-2-(2,4-difluoro-phenyl)-3- ⁇ 4- [4-(4-methylthiazol-2-yl)phenyl]thiazol-2- yl ⁇ -l-(lH-l,2,4-triazol-l-yl)butan-2-ol, (2R,3R)-2-(2,4-difluorophenyl)-3- ⁇ 4-[4- (4-ethylthiazol-2-yl)phenyl]thiazol-2-yl ⁇ -l-(lH-l,2,4-tria
- This reaction proceeds in a solvent such as chloroform, dichloromethan, acetonitrile, dimethylformamide, methanol, ethanol, and the like, and at temperature between 0°C and 100°C for between 1 to 12 hours, preferably at 20°C to 60°C.
- a solvent such as chloroform, dichloromethan, acetonitrile, dimethylformamide, methanol, ethanol, and the like.
- Compound (Nil) where R is hydrogen can also be produced by condensation of a compound N, where X, Y and Q are as above, with chloroacetal, the reaction conditions being about as described in Example 5.
- Specific examples of the compound represented by the formula (IX) may include, for example, the following compounds: (2R,3R) -2- (2,4-difluorophenyl) -3- (3- ⁇ 4- [5-methyl-(l,2,4-thiaziazol-3-yl)] ⁇ henyl ⁇ -l,2,4-thiadiazol-5-yl)-l-( lH- l,2 ) 4-triazol-l-yl)-butan-2-ol, (2R,3R)-2-(2,4-difluorophenyl)-3-(4- ⁇ 4-[5-methyl- (l,2,4-thiadiazol-3-yl)]phenyl ⁇ thiazol-2-yl)-l-( lH-l,2,4-triazol-l-yl)butan-2-ol ) (2R,3R)-2-(2,4-difluorophenyl)-3-(4- ⁇ 4-[5-ethyl-
- This reaction proceeds in a solvent such as chloroform, dichloromethane, acetonitrile, dimethylformamide, methanol, ethanol, tetrahydrofurane and the like in the presence of oxidizing reagent such as iodine, selenium dioxide, n-butyl nitrite and the like, and at temperature between 25°C and 100°C for between 5 to
- Specific examples of the compound represented by the general formula (XI) may include, for example, the following compounds: (2R,3R)-2-(2,4- difluorophenyl)-3- ⁇ 3- [4-(l,2,3-thiadiazol-4-yl)phenyl] -l,2,4-thiadiazol-5-yl ⁇ -l-
- This reaction proceeds in a solvent such as chloroform, dichloromefhane, acetonitrile, dimethylformamide, methanol, ethanol, tetrahydrofurane and the like in the presence of oxidizing reagent such as iodine, selenium dioxide, n-butyl nitrite and the like, and at temperature between 25°C and 100°C for between 5 to
- the desired l-(lH-l,2,4-triazol-l-yl)butan-2-ol derivatives of the formula (I) in which X is a 1,2,4-oxadiazole can be produced by condensation of a compound represented by the formula (XII) with an acid chloride represented by the formula (XIII) in a manner similar to that described in /. Het. Chem. 26, 125 (1989):
- This reaction proceeds in a solvent such as pyridine, pyrazine, quinoline and the like at temperatures between 25°C and 100°C for 5 to 48 hours, preferably at 50°C to 80°C.
- a solvent such as pyridine, pyrazine, quinoline and the like at temperatures between 25°C and 100°C for 5 to 48 hours, preferably at 50°C to 80°C.
- This reaction proceeds in a solvent such as pyridine, pyrazine, quinoline and the like at temperatures between 25°C and 100°C for 5 to 48 hours, preferably at 50°C to 80°C.
- a solvent such as pyridine, pyrazine, quinoline and the like at temperatures between 25°C and 100°C for 5 to 48 hours, preferably at 50°C to 80°C.
- This reaction proceeds in a solvent such as methanol, ethanol, propanol, butanol and the like at temperature between 25°C and 100°C for between 5 to 48 hours, preferably at 50°C to 80°C.
- a solvent such as methanol, ethanol, propanol, butanol and the like at temperature between 25°C and 100°C for between 5 to 48 hours, preferably at 50°C to 80°C.
- the desired l-(lH-l,2,4-triazol-l-yl)butan-2-ol derivatives of the formula (I) in which X is a pyrazole can be produced by condensation of a compound represented by the formula (XXI) with an ⁇ -ketoaldehyde represented by the formula (XNIII) or a dialdehyde represented by the formula (XIX) in a manner similar to that described in /. Het. Chem. 51 (1974):
- This reaction proceeds in a solvent such as methanol, ethanol, propanol, butanol and the like at temperature between 25°C and 100°C for 5 to 48 hours, preferably at 50°C to 80°C.
- a solvent such as methanol, ethanol, propanol, butanol and the like
- Other desired l-(lH-l,2,4-triazol-l-yl)butan-2-ol derivatives of the formula (I) in which X is as defined above can be produced by similar condensation reactions as described in the above processes, using appropriate nucleophiles and electrophiles.
- the starting compounds (II), (XXIII) and (XXIN) can be prepared by using known methods (Konotsu T. et al, Chem. Pharm. Bull, 39, 2241-2246(1991)).
- the starting compounds (III) and (VI) can be prepared by using known methods (Langley, W. O., Organic Synthesis, 1, 127 (1941)).
- the starting compound (N) can be prepared by using known methods (Tsuruoka A. etal, Chem. Pharm. Bull, 46, 623-630(1998)).
- the starting compound (VIII) and (X) can be prepared by using known methods (Corrao, S. L. et al., /. Org. Chem., 55, 4486-4487 (1990)).
- the starting compounds (XII), (XVII), (XXI) and (XN) can be prepared by using known methods (W092/ 17474).
- TMSC ⁇ trime hylsilyl cyanide.
- the manufacture of the pharmaceutically acceptable acid addition salts of 1- (lH-l,2,4-triazol-l-yl)butan-2-ol derivatives of the formula (I) can be carried out by treating a free base of the compound represented by the formula (I) with an acid using a conventional procedure for the salt formation.
- therapeutically acceptable acids useful in the above process are inorganic acids (e.g. hydrochloric acid, hydrobromic acid, phosphoric acid, nitric acid, sulfuric acid) and organic acids (e. g.
- oxalic acid acetic acid, formic acid, trifluoroacetic acid, maleic acid, succinic acid, fumaric acid, tartaric acid, citric acid, salicylic acid, sorbic acid, lactic acid, methanesulfonic acid).
- the compounds of the formula (I) can be converted into hydrates or solvates and their salts by various methods known to those skilled in the art.
- l-(lH-l,2,4-Triazol-l-yl)butan-2-ol derivatives of the formula (I) and pharmaceutically acceptable salts thereof are very active antimycotic agents. They are active against a variety of fungal species, including Candida albicans, Cryptococcus neoformans, Aspergillus fumigatus, Trichophyton spp., Microsporum spp., Exophiala spp., Rhizopus spp., Absidia spp., Blastomyces dermatitidis, and Histoplasma capsulatum.
- the present invention comprises the use of the above compounds for the manufacture of medicaments for the prophylaxis and treatment of mycoses and the corresponding pharmaceutical compositions which comprise l-(lH-l,2,4-triazol-l-yl)butan-2-ol derivatives of the formula (I) as defined above and a pharmaceutically acceptable carrier.
- they are useful in treating topical and mucous Trichophyton or Microsporum species. They may also be used in the treatment of systemic fungal infections caused by, for example, Candida, Cryptococcus, Aspergillus, Paracoccidiodes, Sporotric, Exophiala, Blastomyces or Histoplasma, especially against Aspergillus spp., Rhizopus spp., and Absidia spp.
- Yeast Nitrogen Base (YNB; Difco Lab.) supplemented with 1% glucose and 0.25% K 2 HPO 4 was used as testing medium for yeast, the same medium solidified with 0.2% low melting point agarose (BRL) was used for filamentous fungi. Inoculum size was 1-3 x 10 4 cells/ml, and incubation was performed for 1-2 days at 35°C.
- l-(lH-l,2,4-triazol-l-yl)butan-2-ol derivatives of the formula (I) or salt forms thereof and the like can be administered alone, but will generally be administered in pharmaceutical admixture formulated as appropriate to the particular use and purpose desired, by mixing excipient, binding agent, lubricant, disintegrating agent, coating material, emulsifier, suspending agent, solvent, stabilizer, absorption enhancer and/or ointment base.
- the admixture can be used for oral, injectable, rectal or topical administration.
- medicaments containing a compound of formula I are also an object of the present invention, as is a process for the manufacture of such medicaments, which process comprises bringing one or more compounds of formula I and, if desired, one or more other therapeutically valuable substances into a galenical administration form.
- compositions may be administered orally, for example in the form of tablets, coated tablets, dragees, hard or soft gelatine capsules, solutions, emulsions or suspensions. Administration can also be carried out rectally, for example using suppositories; locally or percutaneously, for example using ointments, creams, gels or solutions; or parenterally, for example using injectable solutions.
- the compounds of the present invention may be admixed with pharmaceutically inert, inorganic or organic excipients.
- suitable excipients for tablets, dragees or hard gelatine capsules include lactose, maize starch or derivatives thereof, talc or stearic acid or salts thereof.
- Suitable excipients for use with soft gelatine capsules include for example vegetable oils, waxes, fats, semi-solid or liquid polyols etc.; according to the nature of the active ingredients it may however be the case that no excipient is needed at all for soft gelatine capsules.
- excipients which may be used include for example water, polyols, saccharose, invert sugar and glucose.
- excipients which may be used include for example water, alcohols, polyols, glycerine, and vegetable oils.
- excipients which may be used include for example natural or hardened oils, waxes, fats and semi-solid or liquid polyols.
- the pharmaceutical compositions may also contain preserving agents, solubilising agents, stabilising agents, wetting agents, emulsifiers, sweeteners, colorants, odorants, salts for the variation of osmotic pressure, buffers, coating agents or antioxidants. They may also contain other therapeutically valuable agents.
- a pharmaceutical formulation for oral administration may be granule, table, sugar coated tablet, capsule, pill, suspension or emulsion, which for parenteral injection, for example, intravenously, intramuscularly or subcutaneously, may be used in the form of a sterile aqueous solution which may contain other substances, for example, salts or glucose to make the solution isotonic.
- the antifungal can also be administered in the form of a suppository or pessary, or they may be applied topically in the form of a lotion, solution, cream, ointment or dusting powder.
- the daily dosage level of l-(lH-l,2,4-triazol-l-yl)butan-2-ol derivatives of the formula (I) of the present invention is from 0.1 to 100 mg/kg when administered by either the oral or parenteral route.
- tablets or capsules can contain from 5 g to 1000 mg of active compound for administration singly or two or more at a time as appropriate.
- the actual dosage can be weight and response of the particular patient.
- l-(lH-l,2,4-Triazol-l-yl)butan-2-ol derivatives of the formula (I) of the present invention and salts thereof have activity against a variety of plant pathogenic fungi, including for example Pyricularia oryzae, Pythium aphanidermatum, Alternaria spp., and Paecilomyces variotii.
- compositions formulated as dusting powders, or granules, seed dressings, aqueous solutions, dispersions or emulsions, dips, sprays or aerosols.
- Such compositions may contain such conventional carriers, diluents or adjuvants as are known and acceptable in agriculture and horticulture.
- Other compounds having herbicidal or insecticidal activity or additional antifungal compositions can be applied in a number of ways, for example they can be applied directly to the plant foliage, stems, branches, seeds or roots or to the soil or other growing medium, and they may be used not only to eradicate disease, but also prophylactically to protect the plants or seeds from fungal attack.
- the following examples illustrate the preferred methods for the preparation of the compounds of the present invention, which are not intended to limit the scope of the invention thereto.
- Example 18 The following compounds in examples 18-20 were prepared in a similar manner to Example 17.
- Example 18 The following compounds in examples 18-20 were prepared in a similar manner to Example 17.
- Example 18
- Hard gelatine capsules each containing the following ingredients were manufactured in conventional manner:
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2001262179A AU2001262179A1 (en) | 2000-04-17 | 2001-04-06 | 1-(h-1,2,4-triazol-1-yl)butan-2-ol derivatives |
CA002405919A CA2405919A1 (en) | 2000-04-17 | 2001-04-06 | 1-(h-1,2,4-triazol-1-yl)butan-2-ol derivatives |
BR0110010-6A BR0110010A (en) | 2000-04-17 | 2001-04-06 | 1- (h-1,2,4-triazol-1-yl) butan-2-ol derivatives |
MXPA02010177A MXPA02010177A (en) | 2000-04-17 | 2001-04-06 | 1-(h-1,2,4-triazol-1-yl)butan-2-ol derivatives. |
EP01936200A EP1286988A2 (en) | 2000-04-17 | 2001-04-06 | 1-(h-1,2,4-triazol-1-yl)butan-2-ol derivatives |
JP2001576796A JP2003531145A (en) | 2000-04-17 | 2001-04-06 | 1- (1H-1,2,4-triazol-1-yl) butan-2-ol derivative |
KR1020027013839A KR20020087490A (en) | 2000-04-17 | 2001-04-06 | 1-(h-1,2,4-triazol-1-yl)butan-2-ol derivatives |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00108367.4 | 2000-04-17 | ||
EP00108367 | 2000-04-17 | ||
EP00112488 | 2000-06-13 | ||
EP00112488.2 | 2000-06-13 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001079196A2 true WO2001079196A2 (en) | 2001-10-25 |
WO2001079196A3 WO2001079196A3 (en) | 2002-02-21 |
Family
ID=26070833
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2001/003956 WO2001079196A2 (en) | 2000-04-17 | 2001-04-06 | 1-(h-1,2,4-triazol-1-yl)butan-2-ol derivatives |
Country Status (10)
Country | Link |
---|---|
US (1) | US6319933B1 (en) |
EP (1) | EP1286988A2 (en) |
JP (1) | JP2003531145A (en) |
KR (1) | KR20020087490A (en) |
CN (1) | CN1423648A (en) |
AU (1) | AU2001262179A1 (en) |
BR (1) | BR0110010A (en) |
CA (1) | CA2405919A1 (en) |
MX (1) | MXPA02010177A (en) |
WO (1) | WO2001079196A2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007502268A (en) * | 2003-08-12 | 2007-02-08 | コリア リサーチ インスティチュート オブ ケミカル テクノロジー | Antifungal azole derivative having fluorovinyl group and process for producing the same |
US7230023B2 (en) | 2001-02-22 | 2007-06-12 | Sankyo Company, Limited | Water-soluble triazole fungicide |
EP1951705A1 (en) * | 2005-10-31 | 2008-08-06 | Daewoong Pharmaceutical Co., Ltd. | Novel antifungal triazole derivatives |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100738228B1 (en) * | 2006-02-22 | 2007-07-12 | 한국화학연구원 | Antifungal azole compounds and process for preparing same |
KR20080062876A (en) * | 2006-12-29 | 2008-07-03 | 주식회사 대웅제약 | Novel antifungal triazole derivatives |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996025410A1 (en) * | 1995-02-17 | 1996-08-22 | Takeda Chemical Industries, Ltd. | Azole compounds, their production and use |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3830240A1 (en) * | 1987-10-14 | 1989-04-27 | Bayer Ag | SUBSTITUTED 1-ARYL-1- (THIAZOL-2-YL) -2- (1,2,4-TRIAZOL-1-YL) - AND - (IMIDAZOL-1-YL) -ETHANOLS, METHODS AND SUBSTITUTED 1-ARYL- 1- (THIAZOL-2-YL) -2-BROMETHANOLE AS INTERMEDIATE PRODUCTS FOR THE PRODUCTION THEREOF AND CONTAINING FUNGICIDES AND PLANT GROWTH REGULATING AGENTS |
GB9002375D0 (en) | 1990-02-02 | 1990-04-04 | Pfizer Ltd | Triazole antifungal agents |
GB9107055D0 (en) | 1991-04-04 | 1991-05-22 | Pfizer Ltd | Triazole antifungal agents |
NZ270418A (en) | 1994-02-07 | 1997-09-22 | Eisai Co Ltd | Polycyclic triazole & imidazole derivatives, antifungal compositions |
NZ328607A (en) | 1996-09-09 | 1999-08-30 | Hoffmann La Roche | Heterocyclically substituted n-benzyl-azolium derivatives and fungicidal compositions |
-
2001
- 2001-03-22 US US09/814,630 patent/US6319933B1/en not_active Expired - Fee Related
- 2001-04-06 BR BR0110010-6A patent/BR0110010A/en not_active IP Right Cessation
- 2001-04-06 EP EP01936200A patent/EP1286988A2/en not_active Withdrawn
- 2001-04-06 WO PCT/EP2001/003956 patent/WO2001079196A2/en not_active Application Discontinuation
- 2001-04-06 MX MXPA02010177A patent/MXPA02010177A/en unknown
- 2001-04-06 AU AU2001262179A patent/AU2001262179A1/en not_active Abandoned
- 2001-04-06 CN CN01808161A patent/CN1423648A/en active Pending
- 2001-04-06 JP JP2001576796A patent/JP2003531145A/en active Pending
- 2001-04-06 CA CA002405919A patent/CA2405919A1/en not_active Abandoned
- 2001-04-06 KR KR1020027013839A patent/KR20020087490A/en not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996025410A1 (en) * | 1995-02-17 | 1996-08-22 | Takeda Chemical Industries, Ltd. | Azole compounds, their production and use |
Non-Patent Citations (1)
Title |
---|
A. TSURUOKA ET AL.: "Synthesis and Antifungal Activity of Novel Thiazole-Containing Triazole Antifungals. II. Optically Acive ER-30346 and Its Derivatives" CHEMICAL AND PHARMACEUTICAL BULLETIN., vol. 46, no. 4, 1998, pages 623-630, XP001030597 PHARMACEUTICAL SOCIETY OF JAPAN. TOKYO., JP ISSN: 0009-2363 cited in the application * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7230023B2 (en) | 2001-02-22 | 2007-06-12 | Sankyo Company, Limited | Water-soluble triazole fungicide |
JP2007502268A (en) * | 2003-08-12 | 2007-02-08 | コリア リサーチ インスティチュート オブ ケミカル テクノロジー | Antifungal azole derivative having fluorovinyl group and process for producing the same |
EP1951705A1 (en) * | 2005-10-31 | 2008-08-06 | Daewoong Pharmaceutical Co., Ltd. | Novel antifungal triazole derivatives |
EP1951705A4 (en) * | 2005-10-31 | 2010-12-15 | Dae Woong Pharma | Novel antifungal triazole derivatives |
US7968579B2 (en) | 2005-10-31 | 2011-06-28 | Daewoong Pharmaceutical Co., Ltd. | Antifungal triazole derivatives |
Also Published As
Publication number | Publication date |
---|---|
CA2405919A1 (en) | 2001-10-25 |
EP1286988A2 (en) | 2003-03-05 |
US20010047017A1 (en) | 2001-11-29 |
MXPA02010177A (en) | 2003-03-10 |
AU2001262179A1 (en) | 2001-10-30 |
KR20020087490A (en) | 2002-11-22 |
WO2001079196A3 (en) | 2002-02-21 |
BR0110010A (en) | 2003-02-18 |
US6319933B1 (en) | 2001-11-20 |
CN1423648A (en) | 2003-06-11 |
JP2003531145A (en) | 2003-10-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7459561B2 (en) | N-substituted carbamoyloxyalkyl-azolium derivatives | |
US6300353B1 (en) | Azoles for treatment of fungal infections | |
HU211474A9 (en) | Azole compounds, their production and use | |
US4062966A (en) | 1-Aryl-2-(1-imidazolyl) alkyl ethers and thioethers | |
US5792780A (en) | Azole compounds, their production and use | |
EP0097469B1 (en) | Triazole antifungal agents | |
JPH1045750A (en) | Azole compound, its production and use | |
EP0829478A2 (en) | N-Benzylimidazolium and N-benzyltriazolium derivatives, their preparation and their use as antifungal and antimycotic agents | |
EP0097014A2 (en) | Triazole antifungal agents | |
US6319933B1 (en) | Azole derivatives | |
EP0321131A2 (en) | Triazole antifungal agents | |
EP0115400B1 (en) | Triazole antifungal agents | |
JPH0649033A (en) | Optically active azole compound and its use | |
US5962686A (en) | N-benzylazolium derivatives | |
EP0133248B1 (en) | 1,2,4-triazol-1-yl-derivatives | |
JPS6320432B2 (en) | ||
EP0889881B1 (en) | New triazoles as therapeutic agents for fungal infections | |
ZA200207604B (en) | 1-(H-1,2,4-triazol-1-yl)butan-2-ol derivatives. | |
AU726495B2 (en) | N-benzylazolium derivatives | |
US6153616A (en) | Triazoles as therapeutic agents for fungal infections | |
JPH11199411A (en) | Triazole-based antifungal agent | |
JPH07228574A (en) | Optically active azole derivative, its production and use thereof | |
HRP970479A2 (en) | N-benzylazolium derivatives | |
MXPA97006855A (en) | N-benily derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CO CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CO CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002/07604 Country of ref document: ZA Ref document number: 200207604 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001262179 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2001 576796 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001936200 Country of ref document: EP Ref document number: 2405919 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2002/010177 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020027013839 Country of ref document: KR Ref document number: 018081614 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 1020027013839 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2001936200 Country of ref document: EP |
|
WWR | Wipo information: refused in national office |
Ref document number: 1020027013839 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001936200 Country of ref document: EP |